Wells Fargo & Company Lowers Inspire Medical Systems (NYSE:INSP) Price Target to $56.00

Key Points

• Wells Fargo cut its price target on Inspire to $56 from $70 and kept an "equal weight" rating, and several other analysts have trimmed targets or moved to neutral/hold, leaving a consensus rating of "Hold."
• Inspire beat Q1 estimates with $0.10 EPS and $204.6M revenue, but management narrowed FY2026 guidance to $0.75–$1.25 EPS and $825M–$875M revenue citing reimbursement/coding and WISeR disruption, prompting a sharp intraday sell-off to $45.82.

Inspire Medical Systems (NYSE:INSP - Get Free Report) had its target price reduced by investment analysts at Wells Fargo & Company from $70.00 to $56.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has an "equal weight" rating on the stock. Wells Fargo & Company's price target points to a potential upside of 22.22% from the company's current price.

Other equities analysts also recently issued reports about the company. Evercore reissued an "outperform" rating on shares of Inspire Medical Systems in a research note on Friday, February 27th. Mizuho cut their target price on Inspire Medical Systems from $70.00 to $55.00 and set an "outperform" rating for the company in a research note on Tuesday. Jefferies Financial Group lowered their price target on Inspire Medical Systems from $81.00 to $66.00 and set a "hold" rating on the stock in a report on Thursday, February 12th. Royal Bank Of Canada restated a "sector perform" rating and issued a $56.00 price target on shares of Inspire Medical Systems in a report on Tuesday, April 14th. Finally, Bank of America restated a "neutral" rating and issued a $53.00 price target on shares of Inspire Medical Systems in a report on Tuesday. Four investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $94.11.

Inspire Medical Systems Price Performance

Shares of INSP stock traded down $9.02 during trading hours on Tuesday, reaching $45.82. 1,025,019 shares of the company's stock were exchanged, compared to its average volume of 1,174,185. The company has a market cap of $1.32 billion, a P/E ratio of 9.15, a price-to-earnings-growth ratio of 2.92 and a beta of 0.83. The company's 50 day moving average is $56.73 and its two-hundred day moving average is $79.64. Inspire Medical Systems has a 1 year low of $44.41 and a 1 year high of $163.35.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last issued its earnings results on Monday, May 4th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.38. The business had revenue of $204.58 million during the quarter, compared to the consensus estimate of $200.04 million. Inspire Medical Systems had a return on equity of 10.96% and a net margin of 15.95%.The company's revenue for the quarter was up 1.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.10 EPS. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. As a group, analysts predict that Inspire Medical Systems will post 1.82 EPS for the current fiscal year.

Institutional Investors Weigh In On Inspire Medical Systems

Large investors have recently bought and sold shares of the stock. Manning & Napier Advisors LLC acquired a new stake in Inspire Medical Systems during the 3rd quarter valued at $32,000. CWM LLC grew its holdings in Inspire Medical Systems by 216.1% during the 4th quarter. CWM LLC now owns 354 shares of the company's stock valued at $33,000 after buying an additional 242 shares during the last quarter. Havemeyer Place LP acquired a new stake in shares of Inspire Medical Systems during the fourth quarter worth $39,000. V Square Quantitative Management LLC acquired a new stake in shares of Inspire Medical Systems during the fourth quarter worth $40,000. Finally, Smartleaf Asset Management LLC boosted its holdings in shares of Inspire Medical Systems by 84.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 449 shares of the company's stock worth $42,000 after purchasing an additional 205 shares during the last quarter. Institutional investors and hedge funds own 94.91% of the company's stock.

Key Headlines Impacting Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q1 results beat estimates — Inspire reported $0.10 EPS (vs. consensus loss) and $204.6M revenue, topping Street expectations and showing modest year-over-year sales growth. This supports the company's underlying business strength. GlobeNewswire: Q1 Results
• Neutral Sentiment: Analyst note: Mizuho cut its price target from $70 to $55 but kept an "outperform" rating — the new target offers almost no upside versus the current price, so it is mixed (still favorable rating but lower conviction on upside). Benzinga
• Neutral Sentiment: Company materials and call transcript are available for investors reviewing management commentary and the details behind the guidance change. Earnings Call Summary (Yahoo)
• Negative Sentiment: Guidance cut — Inspire narrowed FY2026 EPS guidance to $0.75–$1.25 (street ~$1.99) and revenue to $825M–$875M (street ~$961M). Management cited reimbursement/coding issues and WISeR disruption as drivers of the downgrade, which materially reduces expected growth and margins. Seeking Alpha: Guidance & WISeR Disruption
• Negative Sentiment: Analyst downgrades/price-target cuts — Robert W. Baird cut its target to $50 and moved to "neutral"; Bank of America reaffirmed "neutral" with a $53 target. Those moves signal reduced analyst confidence and put further pressure on the shares. The Fly: Baird Note
• Negative Sentiment: Market reaction: coverage and headlines emphasizing the guidance cut and reimbursement uncertainty drove a sharp intraday sell-off (coverage noted a large single-day decline following the update). Yahoo Finance: Stock Reaction

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.